- Home
- RMCO vs COCP Comparison
RMCO vs COCP Comparison
Compare RMCO & COCP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RMCO
- COCP
- Stock Information
- Founded
- RMCO 2021
- COCP 2006
- Country
- RMCO United States
- COCP United States
- Employees
- RMCO N/A
- COCP N/A
- Industry
- RMCO Multi-Sector Companies
- COCP Biotechnology: Pharmaceutical Preparations
- Sector
- RMCO Miscellaneous
- COCP Health Care
- Exchange
- RMCO Nasdaq
- COCP Nasdaq
- Market Cap
- RMCO 14.9M
- COCP 15.4M
- IPO Year
- RMCO N/A
- COCP N/A
- Fundamental
- Price
- RMCO $1.08
- COCP $1.47
- Analyst Decision
- RMCO
- COCP Strong Buy
- Analyst Count
- RMCO 0
- COCP 1
- Target Price
- RMCO N/A
- COCP $7.00
- AVG Volume (30 Days)
- RMCO 60.7K
- COCP 15.8K
- Earning Date
- RMCO 05-27-2025
- COCP 05-27-2025
- Dividend Yield
- RMCO N/A
- COCP N/A
- EPS Growth
- RMCO N/A
- COCP N/A
- EPS
- RMCO N/A
- COCP N/A
- Revenue
- RMCO $807,089.00
- COCP N/A
- Revenue This Year
- RMCO N/A
- COCP N/A
- Revenue Next Year
- RMCO N/A
- COCP N/A
- P/E Ratio
- RMCO N/A
- COCP N/A
- Revenue Growth
- RMCO 65.21
- COCP N/A
- 52 Week Low
- RMCO $0.74
- COCP $1.12
- 52 Week High
- RMCO $1.59
- COCP $3.26
- Technical
- Relative Strength Index (RSI)
- RMCO 44.65
- COCP 52.12
- Support Level
- RMCO $1.12
- COCP $1.46
- Resistance Level
- RMCO $1.19
- COCP $1.79
- Average True Range (ATR)
- RMCO 0.08
- COCP 0.16
- MACD
- RMCO -0.01
- COCP 0.00
- Stochastic Oscillator
- RMCO 7.80
- COCP 40.00
About RMCO Royalty Management Holding Corporation
Royalty Management Holding Corp formed to invest or purchase assets that have current or near-term income to provide the company with accretive cash flow from which it can reinvest in new assets or expand cash flow from existing assets. These assets typically are natural resources assets (including real estate and mining permits), patents, intellectual property, and emerging technologies.
About COCP Cocrystal Pharma Inc.
Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first and in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI).